ID   MYLK_HUMAN              Reviewed;        1914 AA.
AC   Q15746; B4DUE3; D3DN97; O95796; O95797; O95798; O95799; Q14844;
AC   Q16794; Q17S15; Q3ZCP9; Q5MY99; Q5MYA0; Q6P2N0; Q7Z4J0; Q9C0L5;
AC   Q9UBG5; Q9UBY6; Q9UIT9;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   13-JUL-2010, sequence version 4.
DT   10-MAY-2017, entry version 189.
DE   RecName: Full=Myosin light chain kinase, smooth muscle;
DE            Short=MLCK;
DE            Short=smMLCK;
DE            EC=2.7.11.18;
DE   AltName: Full=Kinase-related protein;
DE            Short=KRP;
DE   AltName: Full=Telokin;
DE   Contains:
DE     RecName: Full=Myosin light chain kinase, smooth muscle, deglutamylated form;
GN   Name=MYLK; Synonyms=MLCK, MLCK1, MYLK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 9), AND TISSUE SPECIFICITY.
RC   TISSUE=Hippocampus;
RX   PubMed=8575746; DOI=10.1006/geno.1995.9965;
RA   Potier M.-C., Chelot E., Pekarsky Y., Gardiner K., Rossier J.,
RA   Turnell W.G.;
RT   "The human myosin light chain kinase (MLCK) from hippocampus: cloning,
RT   sequencing, expression, and localization to 3qcen-q21.";
RL   Genomics 29:562-570(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Umbilical vein endothelial cell;
RX   PubMed=9160829; DOI=10.1165/ajrcmb.16.5.9160829;
RA   Garcia J.G.N., Lazar V.L., Gilbert-Mcclain L.I., Gallagher P.J.,
RA   Verin A.D.;
RT   "Myosin light chain kinase in endothelium: molecular cloning and
RT   regulation.";
RL   Am. J. Respir. Cell Mol. Biol. 16:489-494(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2; 3A AND 3B), AND NUCLEOTIDE
RP   SEQUENCE [MRNA] OF 1281-1914 (ISOFORM 4).
RC   TISSUE=Umbilical vein;
RX   PubMed=10198165; DOI=10.1006/geno.1999.5774;
RA   Lazar V.L., Garcia J.G.N.;
RT   "A single human myosin light chain kinase gene (MLCK; MYLK).";
RL   Genomics 57:256-267(1999).
RN   [4]
RP   SEQUENCE REVISION (ISOFORMS 1 AND 2), PROTEIN SEQUENCE OF 457-476 AND
RP   968-985, FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, PHOSPHORYLATION AT
RP   TYR-464 AND TYR-471, CALMODULIN-BINDING, AND ENZYME REGULATION.
RX   PubMed=11113114; DOI=10.1074/jbc.M005270200;
RA   Birukov K.G., Csortos C., Marzilli L., Dudek S., Ma S.-F.,
RA   Bresnick A.R., Verin A.D., Cotter R.J., Garcia J.G.N.;
RT   "Differential regulation of alternatively spliced endothelial cell
RT   myosin light chain kinase isoforms by p60(Src).";
RL   J. Biol. Chem. 276:8567-8573(2001).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 6), NUCLEOTIDE SEQUENCE [GENOMIC
RP   DNA / MRNA] (ISOFORM 8), NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF
RP   1614-1914 (ISOFORM 9/DEL-1790), AND TISSUE SPECIFICITY.
RC   TISSUE=Lung, and Placenta;
RX   PubMed=10536370;
RX   DOI=10.1002/(SICI)1097-4644(19991201)75:3<481::AID-JCB12>3.3.CO;2-X;
RA   Watterson D.M., Schavocky J.P., Guo L., Weiss C., Chlenski A.,
RA   Shrinsky V.P., Van Eldik L.J., Haiech J.;
RT   "Analysis of the kinase-related protein gene found at human chromosome
RT   3q21 in a multi-gene cluster: organization, expression, alternative
RT   splicing and polymorphic marker.";
RL   J. Cell. Biochem. 75:481-491(1999).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Intestinal epithelium;
RX   PubMed=15507455; DOI=10.1074/jbc.M408822200;
RA   Clayburgh D.R., Rosen S., Witkowski E.D., Wang F., Blair S., Dudek S.,
RA   Garcia J.G., Alverdy J.C., Turner J.R.;
RT   "A differentiation-dependent splice variant of myosin light chain
RT   kinase, MLCK1, regulates epithelial tight junction permeability.";
RL   J. Biol. Chem. 279:55506-55513(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION IN CELL CYCLE, AND
RP   SUBCELLULAR LOCATION.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=15020676; DOI=10.1242/jcs.00993;
RA   Dulyaninova N.G., Patskovsky Y.V., Bresnick A.R.;
RT   "The N-terminus of the long MLCK induces a disruption in normal
RT   spindle morphology and metaphase arrest.";
RL   J. Cell Sci. 117:1481-1493(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5).
RC   TISSUE=Cervix carcinoma;
RA   Kikuchi A., Murata-Hori M., Hosoya H.;
RT   "HeLa myosin light chain kinase.";
RL   Submitted (JAN-2000) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 6; 7 AND 8).
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R.,
RA   Buhay C.J., Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R.,
RA   Gunaratne P., Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V.,
RA   Hume J., Jackson A., Khan Z.M., Kovar-Smith C., Lewis L.R.,
RA   Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D., Wei S.,
RA   Wheeler D.A., Wright M.W., Worley K.C., Yuan Y., Zhang Z., Adams C.Q.,
RA   Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clendenning J., Clerc-Blankenburg K.P., Chen R., Chen Z., Davis C.,
RA   Delgado O., Dinh H.H., Dong W., Draper H., Ernst S., Fu G.,
RA   Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., Hao B.,
RA   Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., Jackson L.R.,
RA   Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., Liu J.,
RA   Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., Palmeiri A.,
RA   Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J.,
RA   Zhang X., Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H.,
RA   Reinhardt R., Naylor S.L., Yang H., Olson M., Weinstock G.,
RA   Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 6 AND 8).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1456-1914 (ISOFORM 9/DEL-1790).
RC   TISSUE=Placenta;
RA   Watterson D.M.;
RL   Submitted (NOV-1995) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   INTERACTION WITH CTTN, AND PHOSPHORYLATION AT TYR-464 AND TYR-471 BY
RP   SRC.
RX   PubMed=12408982; DOI=10.1016/S0006-291X(02)02492-0;
RA   Dudek S.M., Birukov K.G., Zhan X., Garcia J.G.N.;
RT   "Novel interaction of cortactin with endothelial cell myosin light
RT   chain kinase.";
RL   Biochem. Biophys. Res. Commun. 298:511-519(2002).
RN   [15]
RP   FUNCTION IN HYPOTONICITY RESPONSE, AND ENZYME REGULATION.
RX   PubMed=11976941; DOI=10.1007/s00424-002-0811-3;
RA   Shen M.-R., Furla P., Chou C.-Y., Ellory J.C.;
RT   "Myosin light chain kinase modulates hypotonicity-induced Ca2+ entry
RT   and Cl- channel activity in human cervical cancer cells.";
RL   Pflugers Arch. 444:276-285(2002).
RN   [16]
RP   ENZYME REGULATION BY CALCIUM.
RX   PubMed=14741352; DOI=10.1016/S0014-5793(03)01456-X;
RA   Geguchadze R., Zhi G., Lau K.S., Isotani E., Persechini A., Kamm K.E.,
RA   Stull J.T.;
RT   "Quantitative measurements of Ca(2+)/calmodulin binding and activation
RT   of myosin light chain kinase in cells.";
RL   FEBS Lett. 557:121-124(2004).
RN   [17]
RP   FUNCTION IN WOUND HEALING.
RX   PubMed=15825080; DOI=10.1053/j.gastro.2005.01.004;
RA   Russo J.M., Florian P., Shen L., Graham W.V., Tretiakova M.S.,
RA   Gitter A.H., Mrsny R.J., Turner J.R.;
RT   "Distinct temporal-spatial roles for rho kinase and myosin light chain
RT   kinase in epithelial purse-string wound closure.";
RL   Gastroenterology 128:987-1001(2005).
RN   [18]
RP   INDUCTION BY TNF, AND TISSUE SPECIFICITY.
RX   PubMed=16835238; DOI=10.1074/jbc.M602164200;
RA   Graham W.V., Wang F., Clayburgh D.R., Cheng J.X., Yoon B., Wang Y.,
RA   Lin A., Turner J.R.;
RT   "Tumor necrosis factor-induced long myosin light chain kinase
RT   transcription is regulated by differentiation-dependent signaling
RT   events. Characterization of the human long myosin light chain kinase
RT   promoter.";
RL   J. Biol. Chem. 281:26205-26215(2006).
RN   [19]
RP   FUNCTION IN EPITHELIAL CELL SURVIVAL, AND ENZYME REGULATION.
RX   PubMed=16723733; DOI=10.1242/jcs.02926;
RA   Connell L.E., Helfman D.M.;
RT   "Myosin light chain kinase plays a role in the regulation of
RT   epithelial cell survival.";
RL   J. Cell Sci. 119:2269-2281(2006).
RN   [20]
RP   FUNCTION IN TRPC5 REGULATION, AND ENZYME REGULATION.
RX   PubMed=16284075; DOI=10.1113/jphysiol.2005.097998;
RA   Shimizu S., Yoshida T., Wakamori M., Ishii M., Okada T., Takahashi M.,
RA   Seto M., Sakurada K., Kiuchi Y., Mori Y.;
RT   "Ca2+-calmodulin-dependent myosin light chain kinase is essential for
RT   activation of TRPC5 channels expressed in HEK293 cells.";
RL   J. Physiol. (Lond.) 570:219-235(2006).
RN   [21]
RP   FUNCTION IN CELL MIGRATION.
RX   PubMed=18710790; DOI=10.1016/j.canlet.2008.05.028;
RA   Zhou X., Liu Y., You J., Zhang H., Zhang X., Ye L.;
RT   "Myosin light-chain kinase contributes to the proliferation and
RT   migration of breast cancer cells through cross-talk with activated
RT   ERK1/2.";
RL   Cancer Lett. 270:312-327(2008).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1438, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [23]
RP   FUNCTION AS PTK2B/PYK2 KINASE, AND INTERACTION WITH PTK2B/PYK2.
RX   PubMed=18587400; DOI=10.1038/ni.1628;
RA   Xu J., Gao X.-P., Ramchandran R., Zhao Y.-Y., Vogel S.M., Malik A.B.;
RT   "Nonmuscle myosin light-chain kinase mediates neutrophil
RT   transmigration in sepsis-induced lung inflammation by activating beta2
RT   integrins.";
RL   Nat. Immunol. 9:880-886(2008).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1438, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=18318008; DOI=10.1002/pmic.200700884;
RA   Han G., Ye M., Zhou H., Jiang X., Feng S., Jiang X., Tian R., Wan D.,
RA   Zou H., Gu J.;
RT   "Large-scale phosphoproteome analysis of human liver tissue by
RT   enrichment and fractionation of phosphopeptides with strong anion
RT   exchange chromatography.";
RL   Proteomics 8:1346-1361(2008).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [26]
RP   INDUCTION BY ANDROGENS.
RX   PubMed=19429448; DOI=10.1016/j.jsbmb.2009.02.002;
RA   Leveille N., Fournier A., Labrie C.;
RT   "Androgens down-regulate myosin light chain kinase in human prostate
RT   cancer cells.";
RL   J. Steroid Biochem. Mol. Biol. 114:174-179(2009).
RN   [27]
RP   FUNCTION IN TUMOR CELL MIGRATION, ACETYLATION AT LYS-608 BY
RP   NAA10/ARD1, INTERACTION WITH NAA10/ARD1, AND MUTAGENESIS OF LYS-608.
RX   PubMed=19826488; DOI=10.1371/journal.pone.0007451;
RA   Shin D.H., Chun Y.-S., Lee K.-H., Shin H.-W., Park J.-W.;
RT   "Arrest defective-1 controls tumor cell behavior by acetylating myosin
RT   light chain kinase.";
RL   PLoS ONE 4:E7451-E7451(2009).
RN   [28]
RP   FUNCTION IN BREAST CANCER.
RX   PubMed=20453870; DOI=10.1038/aps.2010.56;
RA   Cui W.-J., Liu Y., Zhou X.-L., Wang F.-Z., Zhang X.-D., Ye L.-H.;
RT   "Myosin light chain kinase is responsible for high proliferative
RT   ability of breast cancer cells via anti-apoptosis involving p38
RT   pathway.";
RL   Acta Pharmacol. Sin. 31:725-732(2010).
RN   [29]
RP   FUNCTION IN OPTIC NERVE HEAD ASTROCYTE MIGRATION.
RX   PubMed=20375339; DOI=10.1167/iovs.10-5177;
RA   Miao H., Crabb A.W., Hernandez M.R., Lukas T.J.;
RT   "Modulation of factors affecting optic nerve head astrocyte
RT   migration.";
RL   Invest. Ophthalmol. Vis. Sci. 51:4096-4103(2010).
RN   [30]
RP   TISSUE SPECIFICITY, INTERACTION WITH CTTN, AND SUBCELLULAR LOCATION.
RX   PubMed=20053363; DOI=10.1016/j.mvr.2009.12.010;
RA   Brown M., Adyshev D., Bindokas V., Moitra J., Garcia J.G.N.,
RA   Dudek S.M.;
RT   "Quantitative distribution and colocalization of non-muscle myosin
RT   light chain kinase isoforms and cortactin in human lung endothelium.";
RL   Microvasc. Res. 80:75-88(2010).
RN   [31]
RP   PHOSPHORYLATION AT TYR-231; TYR-464; TYR-556; TYR-611; TYR-792;
RP   TYR-846; TYR-1449; TYR-1575 AND TYR-1635 BY ABL1, AND INTERACTION WITH
RP   CTTN AND ABL1.
RX   PubMed=20861316; DOI=10.1091/mbc.E09-10-0876;
RA   Dudek S.M., Chiang E.T., Camp S.M., Guo Y., Zhao J., Brown M.E.,
RA   Singleton P.A., Wang L., Desai A., Arce F.T., Lal R., Van Eyk J.E.,
RA   Imam S.Z., Garcia J.G.N.;
RT   "Abl tyrosine kinase phosphorylates nonmuscle Myosin light chain
RT   kinase to regulate endothelial barrier function.";
RL   Mol. Biol. Cell 21:4042-4056(2010).
RN   [32]
RP   FUNCTION IN MEMBRANE BLEBBING.
RX   PubMed=20181817; DOI=10.1124/mol.110.063859;
RA   Godin C.M., Ferguson S.S.G.;
RT   "The angiotensin II type 1 receptor induces membrane blebbing by
RT   coupling to Rho A, Rho kinase, and myosin light chain kinase.";
RL   Mol. Pharmacol. 77:903-911(2010).
RN   [33]
RP   FUNCTION IN INFLAMMATORY RESPONSE.
RX   PubMed=20139351; DOI=10.1165/rcmb.2009-0197OC;
RA   Mirzapoiazova T., Moitra J., Moreno-Vinasco L., Sammani S.,
RA   Turner J.R., Chiang E.T., Evenoski C., Wang T., Singleton P.A.,
RA   Huang Y., Lussier Y.A., Watterson D.M., Dudek S.M., Garcia J.G.N.;
RT   "Non-muscle myosin light chain kinase isoform is a viable molecular
RT   target in acute inflammatory lung injury.";
RL   Am. J. Respir. Cell Mol. Biol. 44:40-52(2011).
RN   [34]
RP   ENZYME REGULATION.
RX   PubMed=21918590; DOI=10.1021/om200366r;
RA   Blanck S., Cruchter T., Vultur A., Riedel R., Harms K., Herlyn M.,
RA   Meggers E.;
RT   "Organometallic pyridylnaphthalimide complexes as protein kinase
RT   inhibitors.";
RL   Organometallics 30:4598-4606(2011).
RN   [35]
RP   REVIEW ON ASTHMA, AND INDUCTION BY ASTHMA.
RX   PubMed=19011151; DOI=10.1164/rccm.200609-1367OC;
RA   Leguillette R., Laviolette M., Bergeron C., Zitouni N., Kogut P.,
RA   Solway J., Kachmar L., Hamid Q., Lauzon A.-M.;
RT   "Myosin, transgelin, and myosin light chain kinase: expression and
RT   function in asthma.";
RL   Am. J. Respir. Crit. Care Med. 179:194-204(2009).
RN   [36]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2 (ISOFORMS 6 AND 8),
RP   CLEAVAGE OF INITIATOR METHIONINE [LARGE SCALE ANALYSIS] (ISOFORM 6),
RP   CLEAVAGE OF INITIATOR METHIONINE [LARGE SCALE ANALYSIS] (ISOFORM 8),
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [37]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-305; SER-1438; SER-1772;
RP   SER-1776 AND SER-1779, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [38]
RP   STRUCTURE BY NMR OF 1238-1338.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the eighth Ig-like domain of human myosin light
RT   chain kinase.";
RL   Submitted (NOV-2005) to the PDB data bank.
RN   [39]
RP   STRUCTURE BY NMR OF 1742-1760 IN COMPLEX WITH CALMODULIN.
RX   PubMed=18462678; DOI=10.1016/j.str.2008.02.017;
RA   Gsponer J., Christodoulou J., Cavalli A., Bui J.M., Richter B.,
RA   Dobson C.M., Vendruscolo M.;
RT   "A coupled equilibrium shift mechanism in calmodulin-mediated signal
RT   transduction.";
RL   Structure 16:736-746(2008).
RN   [40]
RP   VARIANTS [LARGE SCALE ANALYSIS] ALA-261; ALA-276; HIS-378; VAL-405;
RP   SER-443; GLY-607; ALA-652; CYS-656; MET-692; THR-701; MET-709;
RP   VAL-1527 AND LEU-1588.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [41]
RP   VARIANT AAT7 PRO-1759, VARIANTS VAL-128; HIS-133; ARG-160; CYS-656;
RP   ALA-1085; MET-1213; LYS-1399 AND THR-1754, CHARACTERIZATION OF VARIANT
RP   AAT7 PRO-1759, AND CHARACTERIZATION OF VARIANT THR-1754.
RX   PubMed=21055718; DOI=10.1016/j.ajhg.2010.10.006;
RA   Wang L., Guo D.C., Cao J., Gong L., Kamm K.E., Regalado E., Li L.,
RA   Shete S., He W.Q., Zhu M.S., Offermanns S., Gilchrist D.,
RA   Elefteriades J., Stull J.T., Milewicz D.M.;
RT   "Mutations in myosin light chain kinase cause familial aortic
RT   dissections.";
RL   Am. J. Hum. Genet. 87:701-707(2010).
CC   -!- FUNCTION: Calcium/calmodulin-dependent myosin light chain kinase
CC       implicated in smooth muscle contraction via phosphorylation of
CC       myosin light chains (MLC). Also regulates actin-myosin interaction
CC       through a non-kinase activity. Phosphorylates PTK2B/PYK2 and
CC       myosin light-chains. Involved in the inflammatory response (e.g.
CC       apoptosis, vascular permeability, leukocyte diapedesis), cell
CC       motility and morphology, airway hyperreactivity and other
CC       activities relevant to asthma. Required for tonic airway smooth
CC       muscle contraction that is necessary for physiological and
CC       asthmatic airway resistance. Necessary for gastrointestinal
CC       motility. Implicated in the regulation of endothelial as well as
CC       vascular permeability, probably via the regulation of cytoskeletal
CC       rearrangements. In the nervous system it has been shown to control
CC       the growth initiation of astrocytic processes in culture and to
CC       participate in transmitter release at synapses formed between
CC       cultured sympathetic ganglion cells. Critical participant in
CC       signaling sequences that result in fibroblast apoptosis. Plays a
CC       role in the regulation of epithelial cell survival. Required for
CC       epithelial wound healing, especially during actomyosin ring
CC       contraction during purse-string wound closure. Mediates RhoA-
CC       dependent membrane blebbing. Triggers TRPC5 channel activity in a
CC       calcium-dependent signaling, by inducing its subcellular
CC       localization at the plasma membrane. Promotes cell migration
CC       (including tumor cells) and tumor metastasis. PTK2B/PYK2
CC       activation by phosphorylation mediates ITGB2 activation and is
CC       thus essential to trigger neutrophil transmigration during acute
CC       lung injury (ALI). May regulate optic nerve head astrocyte
CC       migration. Probably involved in mitotic cytoskeletal regulation.
CC       Regulates tight junction probably by modulating ZO-1 exchange in
CC       the perijunctional actomyosin ring. Mediates burn-induced
CC       microvascular barrier injury; triggers endothelial contraction in
CC       the development of microvascular hyperpermeability by
CC       phosphorylating MLC. Essential for intestinal barrier dysfunction.
CC       Mediates Giardia spp.-mediated reduced epithelial barrier function
CC       during giardiasis intestinal infection via reorganization of
CC       cytoskeletal F-actin and tight junctional ZO-1. Necessary for
CC       hypotonicity-induced Ca(2+) entry and subsequent activation of
CC       volume-sensitive organic osmolyte/anion channels (VSOAC) in
CC       cervical cancer cells. Responsible for high proliferative ability
CC       of breast cancer cells through anti-apoptosis.
CC       {ECO:0000269|PubMed:11113114, ECO:0000269|PubMed:11976941,
CC       ECO:0000269|PubMed:15020676, ECO:0000269|PubMed:15825080,
CC       ECO:0000269|PubMed:16284075, ECO:0000269|PubMed:16723733,
CC       ECO:0000269|PubMed:18587400, ECO:0000269|PubMed:18710790,
CC       ECO:0000269|PubMed:19826488, ECO:0000269|PubMed:20139351,
CC       ECO:0000269|PubMed:20181817, ECO:0000269|PubMed:20375339,
CC       ECO:0000269|PubMed:20453870}.
CC   -!- CATALYTIC ACTIVITY: ATP + [myosin light-chain] = ADP + [myosin
CC       light-chain] phosphate.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108;
CC   -!- ENZYME REGULATION: Isoform 1 is activated by phosphorylation on
CC       Tyr-464 and Tyr-471. Isoforms which lack these tyrosine residues
CC       are not regulated in this way. All catalytically active isoforms
CC       require binding to calcium and calmodulin for activation.
CC       Repressed by organometallic pyridylnaphthalimide complexes,
CC       wortmannin, ML-7 (a synthetic naphthalenesulphonyl derivative that
CC       inhibits the binding of ATP to MLCK) and ML-9.
CC       {ECO:0000269|PubMed:11113114, ECO:0000269|PubMed:11976941,
CC       ECO:0000269|PubMed:14741352, ECO:0000269|PubMed:16284075,
CC       ECO:0000269|PubMed:16723733, ECO:0000269|PubMed:21918590}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=6.5 uM for MLC (isoform 1 at 22 degrees Celsius)
CC         {ECO:0000269|PubMed:11113114};
CC         KM=7.2 uM for MLC (isoform 2 at 22 degrees Celsius)
CC         {ECO:0000269|PubMed:11113114};
CC         Vmax=11.9 umol/min/mg enzyme (isoform 1 at 22 degrees Celsius)
CC         {ECO:0000269|PubMed:11113114};
CC         Vmax=10.9 umol/min/mg enzyme (isoform 1 at 22 degrees Celsius)
CC         {ECO:0000269|PubMed:11113114};
CC   -!- SUBUNIT: All isoforms including Telokin bind calmodulin. Interacts
CC       with SVIL (By similarity). Interacts with CTTN; this interaction
CC       is reduced during thrombin-induced endothelial cell (EC)
CC       contraction but is promoted by the barrier-protective agonist
CC       sphingosine 1-phosphate (S1P) within lamellipodia. A complex made
CC       of ABL1, CTTN and MYLK regulates cortical actin-based cytoskeletal
CC       rearrangement critical to sphingosine 1-phosphate (S1P)-mediated
CC       endothelial cell (EC) barrier enhancement. Binds to NAA10/ARD1 and
CC       PTK2B/PYK2. {ECO:0000250, ECO:0000269|PubMed:12408982,
CC       ECO:0000269|PubMed:18462678, ECO:0000269|PubMed:18587400,
CC       ECO:0000269|PubMed:19826488, ECO:0000269|PubMed:20053363,
CC       ECO:0000269|PubMed:20861316}.
CC   -!- INTERACTION:
CC       Q9HD26:GOPC; NbExp=3; IntAct=EBI-968482, EBI-349832;
CC       P16333:NCK1; NbExp=2; IntAct=EBI-968482, EBI-389883;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Cell projection, lamellipodium.
CC       Cleavage furrow. Cytoplasm, cytoskeleton. Note=Localized to stress
CC       fibers during interphase and to the cleavage furrow during
CC       mitosis.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing, Alternative initiation; Named isoforms=11;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=1; Synonyms=Non-muscle isozyme;
CC         IsoId=Q15746-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q15746-2; Sequence=VSP_004791;
CC       Name=3A;
CC         IsoId=Q15746-3; Sequence=VSP_004794;
CC         Note=Ref.3 (AAD15922) sequence differs from that shown due to
CC         frameshifts in positions 1433 and 1439. {ECO:0000305};
CC       Name=3B;
CC         IsoId=Q15746-4; Sequence=VSP_004791, VSP_004794;
CC         Note=Ref.3 (AAD15923) sequence differs from that shown due to
CC         frameshifts in positions 1433 and 1439. {ECO:0000305};
CC       Name=4;
CC         IsoId=Q15746-5; Sequence=VSP_004793;
CC         Note=Ref.3 (AAD15924) sequence differs from that shown due to
CC         frameshifts in positions 1433 and 1439. {ECO:0000305};
CC       Name=Del-1790;
CC         IsoId=Q15746-6; Sequence=VSP_004795;
CC       Name=5; Synonyms=Smooth-muscle isozyme;
CC         IsoId=Q15746-7; Sequence=VSP_018845;
CC         Note=Produced by alternative initiation at Met-923 of isoform
CC         1.;
CC       Name=6; Synonyms=Telokin;
CC         IsoId=Q15746-8; Sequence=VSP_018846;
CC         Note=Produced by alternative initiation at Met-1761 of isoform
CC         1. Has no catalytic activity. Initiator Met-1 is removed.
CC         Contains a N-acetylalanine at position 2.
CC         {ECO:0000244|PubMed:22814378};
CC       Name=7;
CC         IsoId=Q15746-9; Sequence=VSP_053791;
CC       Name=8;
CC         IsoId=Q15746-10; Sequence=VSP_018846, VSP_004795;
CC         Note=Produced by alternative initiation at Met-1761 of isoform
CC         1. Initiator Met-1 is removed. Contains a N-acetylalanine at
CC         position 2. {ECO:0000244|PubMed:22814378};
CC       Name=9;
CC         IsoId=Q15746-11; Sequence=VSP_018845, VSP_004795;
CC         Note=Produced by alternative initiation at Met-923 of isoform
CC         1.;
CC   -!- TISSUE SPECIFICITY: Smooth muscle and non-muscle isozymes are
CC       expressed in a wide variety of adult and fetal tissues and in
CC       cultured endothelium with qualitative expression appearing to be
CC       neither tissue- nor development-specific. Non-muscle isoform 2 is
CC       the dominant splice variant expressed in various tissues. Telokin
CC       has been found in a wide variety of adult and fetal tissues.
CC       Accumulates in well differentiated enterocytes of the intestinal
CC       epithelium in response to tumor necrosis factor (TNF).
CC       {ECO:0000269|PubMed:10536370, ECO:0000269|PubMed:16835238,
CC       ECO:0000269|PubMed:20053363, ECO:0000269|PubMed:8575746}.
CC   -!- INDUCTION: Accumulates in individuals with asthma (at protein
CC       levels). Induced by tumor necrosis factor (TNF). Repressed by
CC       androgens (e.g. R1881). {ECO:0000269|PubMed:16835238,
CC       ECO:0000269|PubMed:19011151, ECO:0000269|PubMed:19429448}.
CC   -!- PTM: Can probably be down-regulated by phosphorylation. Tyrosine
CC       phosphorylation by ABL1 increases kinase activity, reverses MLCK-
CC       mediated inhibition of Arp2/3-mediated actin polymerization, and
CC       enhances CTTN-binding. Phosphorylation by SRC at Tyr-464 and Tyr-
CC       471 promotes CTTN binding. {ECO:0000269|PubMed:11113114,
CC       ECO:0000269|PubMed:12408982, ECO:0000269|PubMed:20861316}.
CC   -!- PTM: The C-terminus is deglutamylated by AGTPBP1/CCP1, AGBL1/CCP4
CC       and AGBL4/CCP6, leading to the formation of Myosin light chain
CC       kinase, smooth muscle, deglutamylated form. The consequences of C-
CC       terminal deglutamylation are unknown (By similarity).
CC       {ECO:0000250}.
CC   -!- PTM: Acetylated at Lys-608 by NAA10/ARD1 via a calcium-dependent
CC       signaling; this acetylation represses kinase activity and reduces
CC       tumor cell migration. {ECO:0000269|PubMed:19826488}.
CC   -!- DISEASE: Aortic aneurysm, familial thoracic 7 (AAT7) [MIM:613780]:
CC       A disease characterized by permanent dilation of the thoracic
CC       aorta usually due to degenerative changes in the aortic wall. It
CC       is primarily associated with a characteristic histologic
CC       appearance known as 'medial necrosis' or 'Erdheim cystic medial
CC       necrosis' in which there is degeneration and fragmentation of
CC       elastic fibers, loss of smooth muscle cells, and an accumulation
CC       of basophilic ground substance. {ECO:0000269|PubMed:21055718}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- MISCELLANEOUS: In asthmatic patients, overexpression promotes
CC       actin filament propulsion, thus contributing to airway
CC       hyperresponsiveness. Some MYLK variants may contribute to acute
CC       lung injury (ALI) susceptibility. Potential therapeutic target in
CC       the treatment of burn edema.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK
CC       Ser/Thr protein kinase family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAD15922.1; Type=Frameshift; Positions=1433; Evidence={ECO:0000305};
CC       Sequence=AAD15923.1; Type=Frameshift; Positions=1433; Evidence={ECO:0000305};
CC       Sequence=AAD15924.1; Type=Frameshift; Positions=1433; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Myosin light-chain kinase
CC       entry;
CC       URL="https://en.wikipedia.org/wiki/Myosin_light-chain_kinase";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/MYLKID43364ch3q21.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X85337; CAA59685.1; -; mRNA.
DR   EMBL; U48959; AAC18423.2; -; mRNA.
DR   EMBL; AF069601; AAD15921.2; -; mRNA.
DR   EMBL; AF069602; AAD15922.1; ALT_FRAME; mRNA.
DR   EMBL; AF069603; AAD15923.1; ALT_FRAME; mRNA.
DR   EMBL; AF069604; AAD15924.1; ALT_FRAME; mRNA.
DR   EMBL; AF096771; AAD51380.1; -; Genomic_DNA.
DR   EMBL; AF096766; AAD51380.1; JOINED; Genomic_DNA.
DR   EMBL; AF096767; AAD51380.1; JOINED; Genomic_DNA.
DR   EMBL; AF096768; AAD51380.1; JOINED; Genomic_DNA.
DR   EMBL; AF096769; AAD51380.1; JOINED; Genomic_DNA.
DR   EMBL; AF096770; AAD51380.1; JOINED; Genomic_DNA.
DR   EMBL; AF096771; AAD51381.1; -; Genomic_DNA.
DR   EMBL; AF096769; AAD51381.1; JOINED; Genomic_DNA.
DR   EMBL; AF096770; AAD51381.1; JOINED; Genomic_DNA.
DR   EMBL; AF096773; AAD54017.1; -; mRNA.
DR   EMBL; AF096774; AAD54018.1; -; mRNA.
DR   EMBL; AF096775; AAD54019.1; -; mRNA.
DR   EMBL; AY424269; AAR29061.1; -; mRNA.
DR   EMBL; AY424270; AAR29062.1; -; mRNA.
DR   EMBL; AY339601; AAQ02673.1; -; mRNA.
DR   EMBL; AB037663; BAB21504.1; -; mRNA.
DR   EMBL; AK300610; BAG62305.1; -; mRNA.
DR   EMBL; AK314412; BAG37033.1; -; mRNA.
DR   EMBL; AK314443; BAG37052.1; -; mRNA.
DR   EMBL; AC020634; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC023165; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471052; EAW79438.1; -; Genomic_DNA.
DR   EMBL; CH471052; EAW79439.1; -; Genomic_DNA.
DR   EMBL; CH471052; EAW79440.1; -; Genomic_DNA.
DR   EMBL; CH471052; EAW79441.1; -; Genomic_DNA.
DR   EMBL; BC100761; AAI00762.2; -; mRNA.
DR   EMBL; BC100762; AAI00763.2; -; mRNA.
DR   EMBL; BC100763; AAI00764.2; -; mRNA.
DR   EMBL; BC064420; AAH64420.2; -; mRNA.
DR   EMBL; X90870; CAA62378.1; -; mRNA.
DR   CCDS; CCDS3023.1; -. [Q15746-3]
DR   CCDS; CCDS43141.1; -. [Q15746-2]
DR   CCDS; CCDS46896.1; -. [Q15746-1]
DR   CCDS; CCDS46897.1; -. [Q15746-8]
DR   CCDS; CCDS58849.1; -. [Q15746-10]
DR   RefSeq; NP_001308238.1; NM_001321309.1.
DR   RefSeq; NP_444253.3; NM_053025.3. [Q15746-1]
DR   RefSeq; NP_444254.3; NM_053026.3. [Q15746-2]
DR   RefSeq; NP_444255.3; NM_053027.3. [Q15746-3]
DR   RefSeq; NP_444256.3; NM_053028.3. [Q15746-4]
DR   RefSeq; NP_444259.1; NM_053031.3. [Q15746-10]
DR   RefSeq; NP_444260.1; NM_053032.3. [Q15746-8]
DR   RefSeq; XP_011511162.1; XM_011512860.2. [Q15746-6]
DR   RefSeq; XP_016861958.1; XM_017006469.1. [Q15746-11]
DR   RefSeq; XP_016861960.1; XM_017006471.1. [Q15746-9]
DR   RefSeq; XP_016861961.1; XM_017006472.1. [Q15746-8]
DR   RefSeq; XP_016861962.1; XM_017006473.1. [Q15746-10]
DR   UniGene; Hs.477375; -.
DR   PDB; 2CQV; NMR; -; A=1238-1338.
DR   PDB; 2K0F; NMR; -; B=1742-1760.
DR   PDB; 2YR3; NMR; -; A=510-601.
DR   PDBsum; 2CQV; -.
DR   PDBsum; 2K0F; -.
DR   PDBsum; 2YR3; -.
DR   ProteinModelPortal; Q15746; -.
DR   SMR; Q15746; -.
DR   BioGrid; 110722; 17.
DR   IntAct; Q15746; 22.
DR   MINT; MINT-2807402; -.
DR   STRING; 9606.ENSP00000353452; -.
DR   BindingDB; Q15746; -.
DR   ChEMBL; CHEMBL2428; -.
DR   GuidetoPHARMACOLOGY; 1552; -.
DR   iPTMnet; Q15746; -.
DR   PhosphoSitePlus; Q15746; -.
DR   BioMuta; MYLK; -.
DR   DMDM; 300669714; -.
DR   EPD; Q15746; -.
DR   MaxQB; Q15746; -.
DR   PaxDb; Q15746; -.
DR   PeptideAtlas; Q15746; -.
DR   PRIDE; Q15746; -.
DR   DNASU; 4638; -.
DR   Ensembl; ENST00000346322; ENSP00000320622; ENSG00000065534. [Q15746-2]
DR   Ensembl; ENST00000354792; ENSP00000346846; ENSG00000065534. [Q15746-2]
DR   Ensembl; ENST00000359169; ENSP00000352088; ENSG00000065534. [Q15746-3]
DR   Ensembl; ENST00000360304; ENSP00000353452; ENSG00000065534. [Q15746-1]
DR   Ensembl; ENST00000360772; ENSP00000354004; ENSG00000065534. [Q15746-3]
DR   Ensembl; ENST00000418370; ENSP00000428967; ENSG00000065534. [Q15746-8]
DR   Ensembl; ENST00000475616; ENSP00000418335; ENSG00000065534. [Q15746-1]
DR   Ensembl; ENST00000578202; ENSP00000463691; ENSG00000065534. [Q15746-10]
DR   Ensembl; ENST00000583087; ENSP00000462118; ENSG00000065534. [Q15746-8]
DR   GeneID; 4638; -.
DR   KEGG; hsa:4638; -.
DR   UCSC; uc003egl.4; human. [Q15746-1]
DR   CTD; 4638; -.
DR   DisGeNET; 4638; -.
DR   GeneCards; MYLK; -.
DR   GeneReviews; MYLK; -.
DR   HGNC; HGNC:7590; MYLK.
DR   HPA; CAB020789; -.
DR   HPA; HPA031677; -.
DR   MalaCards; MYLK; -.
DR   MIM; 600922; gene.
DR   MIM; 613780; phenotype.
DR   neXtProt; NX_Q15746; -.
DR   OpenTargets; ENSG00000065534; -.
DR   Orphanet; 91387; Familial thoracic aortic aneurysm and aortic dissection.
DR   PharmGKB; PA31388; -.
DR   eggNOG; KOG0613; Eukaryota.
DR   eggNOG; ENOG410XQFD; LUCA.
DR   GeneTree; ENSGT00760000118877; -.
DR   HOGENOM; HOG000049287; -.
DR   HOVERGEN; HBG052551; -.
DR   InParanoid; Q15746; -.
DR   KO; K00907; -.
DR   OMA; KYTCEAW; -.
DR   OrthoDB; EOG091G005W; -.
DR   PhylomeDB; Q15746; -.
DR   TreeFam; TF314166; -.
DR   BRENDA; 2.7.11.18; 2681.
DR   Reactome; R-HSA-445355; Smooth Muscle Contraction.
DR   Reactome; R-HSA-5627123; RHO GTPases activate PAKs.
DR   SignaLink; Q15746; -.
DR   SIGNOR; Q15746; -.
DR   ChiTaRS; MYLK; human.
DR   EvolutionaryTrace; Q15746; -.
DR   GeneWiki; MYLK; -.
DR   GenomeRNAi; 4638; -.
DR   PRO; PR:Q15746; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; ENSG00000065534; -.
DR   ExpressionAtlas; Q15746; baseline and differential.
DR   Genevisible; Q15746; HS.
DR   GO; GO:0032154; C:cleavage furrow; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0030027; C:lamellipodium; IDA:UniProtKB.
DR   GO; GO:0001725; C:stress fiber; IDA:UniProtKB.
DR   GO; GO:0003779; F:actin binding; IEA:UniProtKB-KW.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005516; F:calmodulin binding; IEA:UniProtKB-KW.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004687; F:myosin light chain kinase activity; IDA:UniProtKB.
DR   GO; GO:0060414; P:aorta smooth muscle tissue morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0032060; P:bleb assembly; IMP:UniProtKB.
DR   GO; GO:0071476; P:cellular hypotonic response; IDA:UniProtKB.
DR   GO; GO:0006936; P:muscle contraction; TAS:Reactome.
DR   GO; GO:0051928; P:positive regulation of calcium ion transport; IDA:UniProtKB.
DR   GO; GO:0030335; P:positive regulation of cell migration; IDA:UniProtKB.
DR   GO; GO:0090303; P:positive regulation of wound healing; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0006939; P:smooth muscle contraction; ISS:UniProtKB.
DR   GO; GO:0014820; P:tonic smooth muscle contraction; ISS:UniProtKB.
DR   CDD; cd00063; FN3; 1.
DR   CDD; cd14191; STKc_MLCK1; 1.
DR   Gene3D; 2.60.40.10; -; 10.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR015725; MLCK1_kinase_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00041; fn3; 1.
DR   Pfam; PF07679; I-set; 9.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00060; FN3; 1.
DR   SMART; SM00409; IG; 9.
DR   SMART; SM00408; IGc2; 9.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 9.
DR   SUPFAM; SSF49265; SSF49265; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50853; FN3; 1.
DR   PROSITE; PS50835; IG_LIKE; 9.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Actin-binding; Alternative initiation;
KW   Alternative splicing; Aortic aneurysm; ATP-binding; Calcium;
KW   Calmodulin-binding; Cell projection; Complete proteome; Cytoplasm;
KW   Cytoskeleton; Direct protein sequencing; Disease mutation;
KW   Disulfide bond; Immunoglobulin domain; Kinase; Magnesium;
KW   Metal-binding; Nucleotide-binding; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repeat; Serine/threonine-protein kinase;
KW   Transferase.
FT   CHAIN         1   1914       Myosin light chain kinase, smooth muscle.
FT                                /FTId=PRO_0000024354.
FT   CHAIN         1   1910       Myosin light chain kinase, smooth muscle,
FT                                deglutamylated form. {ECO:0000250}.
FT                                /FTId=PRO_0000403731.
FT   DOMAIN       33    122       Ig-like C2-type 1.
FT   DOMAIN      161    249       Ig-like C2-type 2.
FT   DOMAIN      414    503       Ig-like C2-type 3.
FT   DOMAIN      514    599       Ig-like C2-type 4.
FT   DOMAIN      620    711       Ig-like C2-type 5.
FT   DOMAIN      721    821       Ig-like C2-type 6.
FT   REPEAT      868    895       1-1.
FT   REPEAT      896    923       1-2.
FT   REPEAT      924    951       1-3.
FT   REPEAT      952    979       1-4.
FT   REPEAT      980    998       1-5; truncated.
FT   REPEAT      999   1003       2-1; truncated.
FT   REPEAT     1004   1015       2-2.
FT   REPEAT     1016   1027       2-3.
FT   REPEAT     1028   1039       2-4.
FT   REPEAT     1040   1051       2-5.
FT   REPEAT     1052   1063       2-6.
FT   DOMAIN     1098   1186       Ig-like C2-type 7.
FT   DOMAIN     1238   1326       Ig-like C2-type 8.
FT   DOMAIN     1334   1426       Fibronectin type-III.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     1464   1719       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN     1809   1898       Ig-like C2-type 9.
FT   NP_BIND    1470   1478       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      868    998       5 X 28 AA approximate tandem repeats.
FT   REGION      923    963       Actin-binding (calcium/calmodulin-
FT                                sensitive). {ECO:0000250}.
FT   REGION      948    963       Calmodulin-binding. {ECO:0000250}.
FT   REGION      999   1063       6 X 12 AA approximate tandem repeats.
FT   REGION     1061   1460       Actin-binding (calcium/calmodulin-
FT                                insensitive). {ECO:0000250}.
FT   REGION     1711   1774       Calmodulin-binding.
FT   COMPBIAS   1906   1914       Poly-Glu.
FT   ACT_SITE   1585   1585       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING    1493   1493       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     231    231       Phosphotyrosine; by ABL1.
FT                                {ECO:0000269|PubMed:20861316}.
FT   MOD_RES     305    305       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     343    343       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q6PDN3}.
FT   MOD_RES     365    365       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q6PDN3}.
FT   MOD_RES     464    464       Phosphotyrosine; by ABL1 and SRC.
FT                                {ECO:0000269|PubMed:11113114,
FT                                ECO:0000269|PubMed:12408982,
FT                                ECO:0000269|PubMed:20861316}.
FT   MOD_RES     471    471       Phosphotyrosine; by SRC.
FT                                {ECO:0000269|PubMed:11113114,
FT                                ECO:0000269|PubMed:12408982}.
FT   MOD_RES     556    556       Phosphotyrosine; by ABL1.
FT                                {ECO:0000269|PubMed:20861316}.
FT   MOD_RES     608    608       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:19826488}.
FT   MOD_RES     611    611       Phosphotyrosine; by ABL1.
FT                                {ECO:0000269|PubMed:20861316}.
FT   MOD_RES     792    792       Phosphotyrosine; by ABL1.
FT                                {ECO:0000269|PubMed:20861316}.
FT   MOD_RES     846    846       Phosphotyrosine; by ABL1.
FT                                {ECO:0000269|PubMed:20861316}.
FT   MOD_RES     947    947       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q6PDN3}.
FT   MOD_RES    1438   1438       Phosphoserine.
FT                                {ECO:0000244|PubMed:18088087,
FT                                ECO:0000244|PubMed:18318008,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES    1449   1449       Phosphotyrosine; by ABL1.
FT                                {ECO:0000269|PubMed:20861316}.
FT   MOD_RES    1575   1575       Phosphotyrosine; by ABL1.
FT                                {ECO:0000269|PubMed:20861316}.
FT   MOD_RES    1635   1635       Phosphotyrosine; by ABL1.
FT                                {ECO:0000269|PubMed:20861316}.
FT   MOD_RES    1759   1759       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q6PDN3}.
FT   MOD_RES    1760   1760       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q6PDN3}.
FT   MOD_RES    1772   1772       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES    1773   1773       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q6PDN3}.
FT   MOD_RES    1776   1776       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES    1778   1778       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q6PDN3}.
FT   MOD_RES    1779   1779       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   DISULFID    182    233       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    435    487       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    535    583       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    742    805       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID   1119   1170       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID   1830   1882       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   VAR_SEQ       1   1760       Missing (in isoform 6 and isoform 8).
FT                                {ECO:0000303|PubMed:10536370,
FT                                ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_018846.
FT   VAR_SEQ       1   1200       Missing (in isoform 7).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_053791.
FT   VAR_SEQ       1    922       Missing (in isoform 5 and isoform 9).
FT                                {ECO:0000303|PubMed:8575746,
FT                                ECO:0000303|Ref.8}.
FT                                /FTId=VSP_018845.
FT   VAR_SEQ     437    506       VSGIPKPEVAWFLEGTPVRRQEGSIEVYEDAGSHYLCLLKA
FT                                RTRDSGTYSCTASNAQGQLSCSWTLQVER -> G (in
FT                                isoform 2 and isoform 3B).
FT                                {ECO:0000303|PubMed:10198165,
FT                                ECO:0000303|PubMed:15507455}.
FT                                /FTId=VSP_004791.
FT   VAR_SEQ    1473   1545       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:10198165}.
FT                                /FTId=VSP_004793.
FT   VAR_SEQ    1655   1705       Missing (in isoform 3A and isoform 3B).
FT                                {ECO:0000303|PubMed:10198165}.
FT                                /FTId=VSP_004794.
FT   VAR_SEQ    1790   1790       Missing (in isoform Del-1790, isoform 8
FT                                and isoform 9).
FT                                {ECO:0000303|PubMed:10536370,
FT                                ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:8575746}.
FT                                /FTId=VSP_004795.
FT   VARIANT      21     21       P -> H (in dbSNP:rs28497577).
FT                                /FTId=VAR_057106.
FT   VARIANT     128    128       A -> V (in dbSNP:rs143896146).
FT                                {ECO:0000269|PubMed:21055718}.
FT                                /FTId=VAR_065570.
FT   VARIANT     133    133       Q -> H (in dbSNP:rs140148380).
FT                                {ECO:0000269|PubMed:21055718}.
FT                                /FTId=VAR_065571.
FT   VARIANT     160    160       P -> R (in dbSNP:rs111256888).
FT                                {ECO:0000269|PubMed:21055718}.
FT                                /FTId=VAR_065572.
FT   VARIANT     261    261       V -> A (in dbSNP:rs3796164).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040847.
FT   VARIANT     276    276       T -> A (in dbSNP:rs55846245).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040848.
FT   VARIANT     336    336       P -> L (in dbSNP:rs35912339).
FT                                /FTId=VAR_057107.
FT   VARIANT     378    378       R -> H (in dbSNP:rs56378658).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040849.
FT   VARIANT     405    405       M -> V (in dbSNP:rs35436690).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040850.
FT   VARIANT     443    443       P -> S (in dbSNP:rs35156360).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040851.
FT   VARIANT     607    607       R -> G. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040852.
FT   VARIANT     652    652       P -> A (in dbSNP:rs750686734).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040853.
FT   VARIANT     656    656       W -> C (in dbSNP:rs138172035).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:21055718}.
FT                                /FTId=VAR_040854.
FT   VARIANT     692    692       T -> M (in dbSNP:rs776858093).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040855.
FT   VARIANT     701    701       A -> T (in dbSNP:rs142835596).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040856.
FT   VARIANT     709    709       V -> M (in dbSNP:rs112537316).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040857.
FT   VARIANT     845    845       R -> C (in dbSNP:rs3732485).
FT                                /FTId=VAR_057108.
FT   VARIANT     861    861       L -> P (in dbSNP:rs3732486).
FT                                /FTId=VAR_019986.
FT   VARIANT     877    877       V -> M (in dbSNP:rs34542174).
FT                                /FTId=VAR_057109.
FT   VARIANT     914    914       D -> E (in dbSNP:rs3732487).
FT                                /FTId=VAR_019987.
FT   VARIANT    1085   1085       T -> A (in dbSNP:rs75370906).
FT                                {ECO:0000269|PubMed:21055718}.
FT                                /FTId=VAR_065573.
FT   VARIANT    1213   1213       V -> M (found in a patient with familial
FT                                aortic dissections; dbSNP:rs368390254).
FT                                {ECO:0000269|PubMed:21055718}.
FT                                /FTId=VAR_065574.
FT   VARIANT    1399   1399       E -> K (found in a patient with familial
FT                                aortic dissections; dbSNP:rs181663420).
FT                                {ECO:0000269|PubMed:21055718}.
FT                                /FTId=VAR_065575.
FT   VARIANT    1527   1527       A -> V (in dbSNP:rs34982967).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040858.
FT   VARIANT    1588   1588       P -> L (in an ovarian mucinous carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040859.
FT   VARIANT    1754   1754       A -> T (found in a patient with familial
FT                                aortic dissections; binding to calmodulin
FT                                is reduced; significant reduction in
FT                                kinase activity compared to wild-type
FT                                protein). {ECO:0000269|PubMed:21055718}.
FT                                /FTId=VAR_065576.
FT   VARIANT    1759   1759       S -> P (in AAT7; shows minimal cells
FT                                endogenous expression; binding to
FT                                calmodulin is abolished; 6-fold reduction
FT                                in kinase activity compared to wild-type
FT                                protein; dbSNP:rs387906781).
FT                                {ECO:0000269|PubMed:21055718}.
FT                                /FTId=VAR_065577.
FT   MUTAGEN     608    608       K->A: Loss of acetylation and no kinase
FT                                activity repression by NAA10/ARD1.
FT                                {ECO:0000269|PubMed:19826488}.
FT   CONFLICT    147    147       P -> S (in Ref. 2; AAC18423, 3; AAD15922/
FT                                AAD15923, 6; AAR29062, 7; AAQ02673 and
FT                                11; EAW79438/EAW79440). {ECO:0000305}.
FT   CONFLICT    466    466       D -> N (in Ref. 6; AAR29062).
FT                                {ECO:0000305}.
FT   CONFLICT    496    496       L -> V (in Ref. 2; AAC18423, 3; AAD15922,
FT                                6; AAR29062 and 7; AAQ02673).
FT                                {ECO:0000305}.
FT   CONFLICT    681    681       C -> W (in Ref. 2; AAC18423 and 3;
FT                                AAD15921/AAD15922/AAD15923).
FT                                {ECO:0000305}.
FT   CONFLICT    933    933       V -> M (in Ref. 1; CAA59685).
FT                                {ECO:0000305}.
FT   CONFLICT    963    963       S -> P (in Ref. 3; AAD15922).
FT                                {ECO:0000305}.
FT   CONFLICT   1022   1022       P -> A (in Ref. 1; CAA59685).
FT                                {ECO:0000305}.
FT   CONFLICT   1048   1050       KPM -> EAH (in Ref. 1; CAA59685 and 8;
FT                                BAB21504). {ECO:0000305}.
FT   CONFLICT   1162   1162       P -> L (in Ref. 3; AAD15922/AAD15923).
FT                                {ECO:0000305}.
FT   CONFLICT   1210   1210       L -> P (in Ref. 1; CAA59685).
FT                                {ECO:0000305}.
FT   CONFLICT   1280   1280       E -> D (in Ref. 3; AAD15922/AAD15923).
FT                                {ECO:0000305}.
FT   CONFLICT   1284   1284       M -> I (in Ref. 3; AAD15922/AAD15923/
FT                                AAD15924). {ECO:0000305}.
FT   CONFLICT   1300   1300       A -> G (in Ref. 1; CAA59685).
FT                                {ECO:0000305}.
FT   CONFLICT   1316   1316       L -> S (in Ref. 1; CAA59685).
FT                                {ECO:0000305}.
FT   CONFLICT   1326   1326       T -> S (in Ref. 1; CAA59685).
FT                                {ECO:0000305}.
FT   CONFLICT   1478   1478       V -> C (in Ref. 1; CAA59685).
FT                                {ECO:0000305}.
FT   CONFLICT   1511   1511       S -> T (in Ref. 3; AAD15922/AAD15923).
FT                                {ECO:0000305}.
FT   CONFLICT   1518   1518       H -> P (in Ref. 6; AAR29061/AAR29062).
FT                                {ECO:0000305}.
FT   CONFLICT   1563   1563       I -> T (in Ref. 1; CAA59685).
FT                                {ECO:0000305}.
FT   CONFLICT   1609   1609       A -> P (in Ref. 1; CAA59685).
FT                                {ECO:0000305}.
FT   CONFLICT   1634   1634       N -> I (in Ref. 6; AAR29061/AAR29062).
FT                                {ECO:0000305}.
FT   CONFLICT   1639   1640       GY -> D (in Ref. 3; AAD15922/AAD15923/
FT                                AAD15924). {ECO:0000305}.
FT   CONFLICT   1639   1639       G -> R (in Ref. 1; CAA59685).
FT                                {ECO:0000305}.
FT   CONFLICT   1648   1648       G -> R (in Ref. 1; CAA59685).
FT                                {ECO:0000305}.
FT   CONFLICT   1658   1659       LS -> PF (in Ref. 1; CAA59685).
FT                                {ECO:0000305}.
FT   CONFLICT   1676   1676       A -> P (in Ref. 6; AAR29061/AAR29062).
FT                                {ECO:0000305}.
FT   CONFLICT   1710   1711       CT -> LA (in Ref. 1; CAA59685).
FT                                {ECO:0000305}.
FT   CONFLICT   1897   1897       L -> H (in Ref. 3; AAD15922/AAD15923/
FT                                AAD15924). {ECO:0000305}.
FT   STRAND      512    518       {ECO:0000244|PDB:2YR3}.
FT   STRAND      523    526       {ECO:0000244|PDB:2YR3}.
FT   STRAND      531    534       {ECO:0000244|PDB:2YR3}.
FT   STRAND      536    541       {ECO:0000244|PDB:2YR3}.
FT   STRAND      546    553       {ECO:0000244|PDB:2YR3}.
FT   STRAND      560    562       {ECO:0000244|PDB:2YR3}.
FT   STRAND      565    570       {ECO:0000244|PDB:2YR3}.
FT   STRAND      581    586       {ECO:0000244|PDB:2YR3}.
FT   STRAND      591    595       {ECO:0000244|PDB:2YR3}.
FT   STRAND      598    601       {ECO:0000244|PDB:2YR3}.
FT   STRAND     1239   1241       {ECO:0000244|PDB:2CQV}.
FT   STRAND     1246   1250       {ECO:0000244|PDB:2CQV}.
FT   STRAND     1255   1266       {ECO:0000244|PDB:2CQV}.
FT   STRAND     1268   1277       {ECO:0000244|PDB:2CQV}.
FT   STRAND     1281   1288       {ECO:0000244|PDB:2CQV}.
FT   STRAND     1290   1297       {ECO:0000244|PDB:2CQV}.
FT   TURN       1302   1304       {ECO:0000244|PDB:2CQV}.
FT   STRAND     1306   1313       {ECO:0000244|PDB:2CQV}.
FT   STRAND     1318   1320       {ECO:0000244|PDB:2CQV}.
FT   STRAND     1323   1328       {ECO:0000244|PDB:2CQV}.
FT   HELIX      1743   1759       {ECO:0000244|PDB:2K0F}.
SQ   SEQUENCE   1914 AA;  210715 MW;  2D094E161CE2D4BA CRC64;
     MGDVKLVASS HISKTSLSVD PSRVDSMPLT EAPAFILPPR NLCIKEGATA KFEGRVRGYP
     EPQVTWHRNG QPITSGGRFL LDCGIRGTFS LVIHAVHEED RGKYTCEATN GSGARQVTVE
     LTVEGSFAKQ LGQPVVSKTL GDRFSAPAVE TRPSIWGECP PKFATKLGRV VVKEGQMGRF
     SCKITGRPQP QVTWLKGNVP LQPSARVSVS EKNGMQVLEI HGVNQDDVGV YTCLVVNGSG
     KASMSAELSI QGLDSANRSF VRETKATNSD VRKEVTNVIS KESKLDSLEA AAKSKNCSSP
     QRGGSPPWAA NSQPQPPRES KLESCKDSPR TAPQTPVLQK TSSSITLQAA RVQPEPRAPG
     LGVLSPSGEE RKRPAPPRPA TFPTRQPGLG SQDVVSKAAN RRIPMEGQRD SAFPKFESKP
     QSQEVKENQT VKFRCEVSGI PKPEVAWFLE GTPVRRQEGS IEVYEDAGSH YLCLLKARTR
     DSGTYSCTAS NAQGQLSCSW TLQVERLAVM EVAPSFSSVL KDCAVIEGQD FVLQCSVRGT
     PVPRITWLLN GQPIQYARST CEAGVAELHI QDALPEDHGT YTCLAENALG QVSCSAWVTV
     HEKKSSRKSE YLLPVAPSKP TAPIFLQGLS DLKVMDGSQV TMTVQVSGNP PPEVIWLHNG
     NEIQESEDFH FEQRGTQHSL CIQEVFPEDT GTYTCEAWNS AGEVRTQAVL TVQEPHDGTQ
     PWFISKPRSV TASLGQSVLI SCAIAGDPFP TVHWLRDGKA LCKDTGHFEV LQNEDVFTLV
     LKKVQPWHAG QYEILLKNRV GECSCQVSLM LQNSSARALP RGREPASCED LCGGGVGADG
     GGSDRYGSLR PGWPARGQGW LEEEDGEDVR GVLKRRVETR QHTEEAIRQQ EVEQLDFRDL
     LGKKVSTKTL SEDDLKEIPA EQMDFRANLQ RQVKPKTVSE EERKVHSPQQ VDFRSVLAKK
     GTSKTPVPEK VPPPKPATPD FRSVLGGKKK LPAENGSSSA ETLNAKAVES SKPLSNAQPS
     GPLKPVGNAK PAETLKPMGN AKPAETLKPM GNAKPDENLK SASKEELKKD VKNDVNCKRG
     HAGTTDNEKR SESQGTAPAF KQKLQDVHVA EGKKLLLQCQ VSSDPPATII WTLNGKTLKT
     TKFIILSQEG SLCSVSIEKA LPEDRGLYKC VAKNDAGQAE CSCQVTVDDA PASENTKAPE
     MKSRRPKSSL PPVLGTESDA TVKKKPAPKT PPKAAMPPQI IQFPEDQKVR AGESVELFGK
     VTGTQPITCT WMKFRKQIQE SEHMKVENSE NGSKLTILAA RQEHCGCYTL LVENKLGSRQ
     AQVNLTVVDK PDPPAGTPCA SDIRSSSLTL SWYGSSYDGG SAVQSYSIEI WDSANKTWKE
     LATCRSTSFN VQDLLPDHEY KFRVRAINVY GTSEPSQESE LTTVGEKPEE PKDEVEVSDD
     DEKEPEVDYR TVTINTEQKV SDFYDIEERL GSGKFGQVFR LVEKKTRKVW AGKFFKAYSA
     KEKENIRQEI SIMNCLHHPK LVQCVDAFEE KANIVMVLEI VSGGELFERI IDEDFELTER
     ECIKYMRQIS EGVEYIHKQG IVHLDLKPEN IMCVNKTGTR IKLIDFGLAR RLENAGSLKV
     LFGTPEFVAP EVINYEPIGY ATDMWSIGVI CYILVSGLSP FMGDNDNETL ANVTSATWDF
     DDEAFDEISD DAKDFISNLL KKDMKNRLDC TQCLQHPWLM KDTKNMEAKK LSKDRMKKYM
     ARRKWQKTGN AVRAIGRLSS MAMISGLSGR KSSTGSPTSP LNAEKLESEE DVSQAFLEAV
     AEEKPHVKPY FSKTIRDLEV VEGSAARFDC KIEGYPDPEV VWFKDDQSIR ESRHFQIDYD
     EDGNCSLIIS DVCGDDDAKY TCKAVNSLGE ATCTAELIVE TMEEGEGEGE EEEE
//
